Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

被引：1
|
作者：
Schwab, C. L. [1 ]
English, D. P. [1 ]
Black, J. D. [1 ]
Lopez, S. [2 ]
Bellone, S. [1 ]
Roque, D. M. [3 ]
Ratner, E. S. [1 ]
Silasi, D. A. [1 ]
Azodi, M. [1 ]
Rutherford, T. J. [1 ]
Schwartz, P. E. [1 ]
Santin, A. [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Univ Campus Biomed Rome, Rome, Italy
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 137卷
关键词：
D O I：
10.1016/j.ygyno.2015.01.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [31] Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase
    Baasner, S
    vonMelchner, H
    Klenner, T
    Hilgard, P
    Beckers, T
    ONCOGENE, 1996, 13 (05) : 901 - 911
  • [32] Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).
    Lee, Kyoungmin
    Lee, Kyung-Hun
    Kim, Dong-Wan
    Yoon, Jeesun
    Choi, Wonyoung
    Lee, Youngjoo
    Choi, Yoon Ji
    Lee, Soohyeon
    Kim, Ju Won
    Ryu, Hyewon
    Koo, Dong-Hoe
    Lee, Yun-Gyoo
    Jeung, Hei-Cheul
    Lee, Min-Young
    Lee, Namsu
    Kang, Myoung Joo
    Lee, Ji Eun
    Hong, Sook Hee
    Kang, Eun Joo
    Park, Inhae
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
    Zhu, Liancheng
    Lopez, Salvatore
    Bellone, Stefania
    Black, Jonathan
    Cocco, Emiliano
    Zigras, Tiffany
    Predolini, Federica
    Bonazzoli, Elena
    Bussi, Beatrice
    Stuhmer, Zachary
    Schwab, Carlton L.
    English, Diana P.
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    TUMOR BIOLOGY, 2015, 36 (07) : 5505 - 5513
  • [34] Sensitivity to the HER2 tyrosine kinase inhibitor lapatinib in breast cancer cells overexpressing truncated HER2 receptor (P95HER-2)
    Scaltriti, Maurizio
    Di Cosimo, Serena
    Ocana, Alberto
    Guzman, Marta
    Cortes, Javier
    Rojo, Federico
    Baselga, Jose
    ANNALS OF ONCOLOGY, 2006, 17 : 58 - 58
  • [35] Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
    Wainberg, Zev A.
    Anghel, Adrian
    Desai, Amrita J.
    Ayala, Raul
    Luo, Tong
    Safran, Brent
    Fejzo, Marlena S.
    Hecht, J. Randolph
    Slamon, Dennis J.
    Finn, Richard S.
    CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1509 - 1519
  • [36] Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
    Sun, Ying
    Chen, Beibei
    Li, Jisheng
    Peng, Ling
    Li, Shuguang
    Yu, Xuejun
    Li, Li
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7165 - 7174
  • [37] Afatinib, an Irreversible ErbB Family Blocker, Demonstrates Remarkable Activity Against HER2 Amplified Uterine Serous Endometrial Cancer In Vitro
    Schwab, Carlton L.
    Roque, Dana M.
    English, Diana P.
    Bellone, Stefania
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    REPRODUCTIVE SCIENCES, 2014, 21 (03) : 214A - 215A
  • [38] Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
    Johnston, Stephen R. D.
    Leary, Alex
    DRUGS OF TODAY, 2006, 42 (07) : 441 - 453
  • [39] Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
    Montemurro, Filippo
    Valabrega, Giorgio
    Aglietta, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 257 - 268
  • [40] Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients
    Carmona, F. Javier
    Hyman, David
    Ulaner, Gary
    Erinjeri, Joe
    Bouvier, Nancy
    Won, Helen
    Cutler, Richard
    Al Alani
    Berger, Michael
    Baselga, Jose
    Scaltriti, Maurizio
    CANCER RESEARCH, 2016, 76
12345